Teva Pharmaceuticals Europe with support from VCCP Health
Janssen with support from Health4Brands London
Napp with support from woolley pau gyro
RB with support from Cello Health
Janssen with support from Health4Brands London
Prezista (darunavir) is the main product of the Janssen HIV
Franchise. It was launched in EMEA in 2006 in highly experienced
patients and since then, it has steadily and consistently increased the
number of indications to retain relevance for the brand’s target
audience. At the time of the launch, the different countries in the EMEA
region developed their own individual creative campaigns.
In 2010, the EMEA region unified all the
communications with one campaign that communicated potency and
leadership. By 2013, Prezista was already leader in its class. The
market landscape changed significantly, with more products available,
the launch of the single tablet regimens (STRs) and the focus on
long-term treatment vs the old paradigm of keeping patients
alive.
At this point, Janssen EMEA team and the marketing teams from the affiliates decided that it was time to revitalise the strategy and campaign. The strategy was developed in a one-day workshop involving representation of key local affiliates. The brand positioning was revised, keeping the essence but completing it and adapting it to the new times. It developed a new single-minded proposition that left behind the well-known potency of Prezista (efficacy now is a given) to base the communication on a customer insight.
This was an effective and simple tactical programme that showed a clear process for revitalising Prezista’s positioning, and changed perceptions. This entry showed good co-creation with affiliates, and local adaption.
Entry deadline | 25 August 2023 |
Extended entry deadline | 1 September 2023* *additional fee applies |
Judging Day | 10 October 2023 |
Company/Team of the Year Interviews | 3 November 2023 |
PMEA Event | 22 November 2023 |